InNexus Biotechnology has announced that it has entered into a collaboration agreement with the National Cancer Institute to research antibody-based technologies developed by InNexus. InNexus has collaborations with XERIS Pharmaceuticals, Genhelix, Cephalon, Affimed and GlaxoSmithKline
